Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    An economic case for a cardiovascular polypill? A cost analysis of the Kanyini GAP trial

    Access Status
    Fulltext not available
    Authors
    Laba, T.
    Hayes, A.
    Lo, S.
    Peiris, D.
    Usherwood, T.
    Hillis, G.
    Rafter, N.
    Reid, Christopher
    Tonkin, A.
    Webster, R.
    Neal, B.
    Cass, A.
    Patel, A.
    Rodgers, A.
    Jan, S.
    Date
    2014
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Laba, T. and Hayes, A. and Lo, S. and Peiris, D. and Usherwood, T. and Hillis, G. and Rafter, N. et al. 2014. An economic case for a cardiovascular polypill? A cost analysis of the Kanyini GAP trial. Medical Journal of Australia. 201 (11): pp. 671-673.
    Source Title
    Medical Journal of Australia
    DOI
    10.5694/mja14.00266
    ISSN
    0025-729X
    School
    Department of Health Policy and Management
    URI
    http://hdl.handle.net/20.500.11937/23207
    Collection
    • Curtin Research Publications
    Abstract

    Objective: To measure the costs of a polypill strategy and compare them with those of usual care in people with established cardiovascular disease (CVD) or at similarly high cardiovascular risk. Design: A within-trial cost analysis of polypill-based care versus usual care with separate medications, using data from the Kanyini Guidelines Adherence with the Polypill (GAP) trial and linked health service and medication administrative claims data. Participants: Kanyini GAP participants who consented to Australian Medicare record access. Main outcome measures: Mean health service and pharmaceutical expenditure per patient per year, estimated with generalised linear models. Costs during the trial (randomisation January 2010 – May 2012, median follow-up 19 months, maximum follow-up 36 months) were inflated to 2012 costs. Results: Our analysis showed a statistically significantly lower mean pharmaceutical expenditure of $989 (95% CI, $648–$1331) per patient per year in the polypill arm compared with usual care (P < 0.001; adjusted, excluding polypill cost). No significant difference was shown in health service expenditure. Conclusions: This study provides evidence of significant cost savings to the taxpayer and Australian Government through the introduction of a CVD polypill strategy. The savings will be less now than during the trial due to subsequent reductions in the costs of usual care. Nonetheless, given the prevalence of CVD in Australia, the introduction of this polypill could increase considerably the efficiency of health care expenditure in Australia.

    Related items

    Showing items related by title, author, creator and subject.

    • The Effect of a Cardiovascular Polypill Strategy on Pill Burden.
      Truelove, M.; Patel, A.; Bompoint, S.; Brown, A.; Cass, A.; Hillis, G.; Peiris, D.; Rafter, N.; Reid, Christopher; Rodgers, A.; Tonkin, A.; Usherwood, T.; Webster, R.; Kanyini GAP Collaboration (2015)
      AIMS: Recent trials of cardiovascular polypills in high-risk populations show improvements in use of cardiovascular preventive treatments, compared to usual care. We describe patterns of pill burden in Australian practice, ...
    • Rationale and design of the Kanyini guidelines adherence with the polypill (Kanyini-GAP) study: A randomised controlled trial of a polypill-based strategy amongst Indigenous and non Indigenous people at high cardiovascular risk
      Liu, H.; Patel, A.; Brown, A.; Eades, S.; Hayman, N.; Jan, S.; Ring, I.; Stewart, G.; Tonkin, A.; Weeramanthri, T.; Wade, V.; Rodgers, A.; Usherwood, T.; Neal, B.; Peiris, D.; Burke, H.; Reid, Christopher; Cass, A. (2010)
      Background. The Kanyini Guidelines Adherence with the Polypill (Kanyini-GAP) Study aims to examine whether a polypill-based strategy (using a single capsule containing aspirin, a statin and two blood pressure-lowering ...
    • A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk
      Patel, A.; Cass, A.; Peiris, D.; Usherwood, T.; Brown, A.; Jan, S.; Neal, B.; Hillis, G.; Rafter, N.; Tonkin, A.; Webster, R.; Billot, L.; Bompoint, S.; Burch, C.; Burke, H.; Hayman, N.; Molanus, B.; Reid, Christopher; Shiel, L.; Togni, S.; Rodgers, A. (2015)
      Background: Most individuals at high cardiovascular disease (CVD) risk worldwide do not receive any or optimal preventive drugs. We aimed to determine whether fixed dose combinations of generic drugs (‘polypills’) would ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.